Interferons

• 

  Subject Areas on Research

  • A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. 
  • A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. 
  • Abnormal production of interleukin-1 by microglia from trisomy 16 mice. 
  • Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. 
  • Adjuvant high-dose interferon therapy for high-risk melanoma. 
  • An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. 
  • An In Vivo Model of Echovirus-Induced Meningitis Defines the Differential Roles of Type I and Type III Interferon Signaling in Central Nervous System Infection. 
  • Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas. 
  • Assays to measure plasma membrane and cytoskeletal changes in interferon-treated cells. 
  • Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. 
  • Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. 
  • CD8+ cell lines isolated from HIV-1-infected children have potent soluble HIV-1 inhibitory activity that differs from beta-chemokines. 
  • Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. 
  • Characterization of serum proteins associated with IL28B genotype among patients with chronic hepatitis C. 
  • Chromosome 19 microRNAs exert antiviral activity independent from type III interferon signaling. 
  • Chronic myelogenous leukemia. 
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. 
  • Clinical relevance of hepatitis B viral mutations. 
  • Computational Analysis of Targeting SARS-CoV-2, Viral Entry Proteins ACE2 and TMPRSS2, and Interferon Genes by Host MicroRNAs. 
  • Constitutive Interferon Maintains GBP Expression Required for Release of Bacterial Components Upstream of Pyroptosis and Anti-DNA Responses. 
  • Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. 
  • Defining the spatial relationship between hepatitis C virus infection and interferon-stimulated gene induction in the human liver. 
  • Dengue Virus Selectively Annexes Endoplasmic Reticulum-Associated Translation Machinery as a Strategy for Co-opting Host Cell Protein Synthesis. 
  • Dengue Virus Targets Nrf2 for NS2B3-Mediated Degradation Leading to Enhanced Oxidative Stress and Viral Replication. 
  • Differential Induction of Immunogenic Cell Death and Interferon Expression in Cancer Cells by Structured ssRNAs. 
  • Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression. 
  • Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. 
  • Effect of interferon on murine leukemia virus infection. II. Synthesis of viral components in exogenous infection. 
  • Enterovirus Replication and Dissemination Are Differentially Controlled by Type I and III Interferons in the Gastrointestinal Tract. 
  • Factors influencing the participation of gastroenterologists and hepatologists in clinical research. 
  • FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus. 
  • Gamma (immune) interferon produced by leukocytes from a patients with a T cell proliferation disease. 
  • Gamma (immune) interferon production by leukocytes from a patient with a TG cell proliferative disease. 
  • Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. 
  • Genetic variation in IL28B: impact on drug development for chronic hepatitis C infection. 
  • Guanylate Binding Proteins Restrict Leishmania donovani Growth in Nonphagocytic Cells Independent of Parasitophorous Vacuolar Targeting. 
  • HIV-1-negative female sex workers sustain high cervical IFNɛ, low immune activation, and low expression of HIV-1-required host genes. 
  • HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. 
  • Hairy cell leukemia: an elusive but treatable disease. 
  • Hepatitis C and depressive symptoms: psychological and social factors matter more than liver injury. 
  • Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype. 
  • Hepatitis C. 
  • Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. 
  • High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients. 
  • Human Lung Stem Cell-Based Alveolospheres Provide Insights into SARS-CoV-2-Mediated Interferon Responses and Pneumocyte Dysfunction. 
  • IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. 
  • IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. 
  • IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. 
  • IL28B in the era of direct-acting antivirals for hepatitis C. 
  • IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin. 
  • IRG proteins: key mediators of interferon-regulated host resistance to intracellular pathogens. 
  • ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. 
  • Immune activation by bacterial DNA: a new genetic code. 
  • Immune-profiling of SARS-CoV-2 viremic patients reveals dysregulated innate immune responses. 
  • Immunity-related GTPase M (IRGM) proteins influence the localization of guanylate-binding protein 2 (GBP2) by modulating macroautophagy. 
  • Immunobiology of human gliomas. 
  • Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study. 
  • Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV. 
  • Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013. 
  • In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome. 
  • Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy. 
  • Induction of superoxide anion and nitric oxide production in cultured microglia. 
  • Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. 
  • Influenza research in the Soviet Union--1974. 
  • Inhibition of human natural killer cell activity by a synthetic peptide homologous to a conserved region in the retroviral protein, p15E. 
  • Innate Antiviral Immunity in the Skin. 
  • Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. 
  • Interferon Inhibition Enhances the Pilot-Scale Production of Rabies Virus in Human Diploid MRC-5 Cells. 
  • Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase. 
  • Interferon effects on microfilament organization, cellular fibronectin distribution, and cell motility in human fibroblasts. 
  • Interferon in the treatment of cutaneous T-cell lymphoma. 
  • Interferon increases the abundance of submembranous microfilaments in HeLa-S3 cells in suspension culture. 
  • Interferon inhibits the redistribution of cell surface components. 
  • Interferon production in mixed cultures of murine leukocytes and syngeneic L1210 leukemia cells. 
  • Interferon-Inducible E3 Ligase RNF213 Facilitates Host-Protective Linear and K63-Linked Ubiquitylation of Toxoplasma gondii Parasitophorous Vacuoles. 
  • Interferon-Inducible GTPases in Host Resistance, Inflammation and Disease. 
  • Interferon-dependent immunoproteasome activity during mouse adenovirus type 1 infection. 
  • Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. 
  • Interferon-mediated protection of B16 melanoma cells from cytotoxicity by activated macrophages. 
  • Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. 
  • Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. 
  • Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. 
  • Intracellular innate immune cascades and interferon defenses that control hepatitis C virus. 
  • Irgm1 protects hematopoietic stem cells by negative regulation of IFN signaling. 
  • Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals. 
  • Lost in translation? IL28B's discovery and the journey back to the patient. 
  • Management of hepatitis C virus infection: the basics. 
  • Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. 
  • Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. 
  • Mucosal melanoma. 
  • Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma. 
  • Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures. 
  • NF-kappa B and transcriptional control of renal epithelial-inducible nitric oxide synthase. 
  • Partners in anti-crime: how interferon-inducible GTPases and autophagy proteins team up in cell-intrinsic host defense. 
  • PharmGKB summary: peginterferon-α pathway. 
  • Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. 
  • Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection. 
  • Predictors of consent to pharmacogenomics testing in the IDEAL study. 
  • Prospects for treatment of human retrovirus-associated diseases. 
  • RNA modification of an RNA modifier prevents self-RNA sensing. 
  • Regulation of hepatic innate immunity by hepatitis C virus. 
  • Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. 
  • STING suppresses bone cancer pain via immune and neuronal modulation. 
  • SUMOylation Connects Cell Stress Responses and Inflammatory Control: Lessons From the Gut as a Model Organ. 
  • Signaling from the RNA sensor RIG-I is regulated by ufmylation. 
  • The Host Response to Viral Infections Reveals Common and Virus-Specific Signatures in the Peripheral Blood. 
  • The IFN-inducible GTPase LRG47 (Irgm1) negatively regulates TLR4-triggered proinflammatory cytokine production and prevents endotoxemia. 
  • The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. 
  • The favorable IFNL3 genotype escapes mRNA decay mediated by AU-rich elements and hepatitis C virus-induced microRNAs. 
  • The immunologic properties of DNA. 
  • The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. 
  • The role of innate immunity in the induction of autoimmunity. 
  • Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development. 
  • Traumatic Brain Injury Causes Chronic Cortical Inflammation and Neuronal Dysfunction Mediated by Microglia. 
  • Treatment of advanced colorectal cancer. 
  • Treatment of hepatitis C in special populations. 
  • Treatment of intracranial alphavirus infections in mice by a combination of specific antibodies and an interferon inducer. 
  • Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma. 
  • Type III Interferons Produced by Human Placental Trophoblasts Confer Protection against Zika Virus Infection. 
  • Type III Interferons in Antiviral Defenses at Barrier Surfaces. 
  • Type III interferon signaling restricts enterovirus 71 infection of goblet cells. 
  • Using Stepwise Pharmacogenomics and Proteomics to Predict Hepatitis C Treatment Response in Difficult to Treat Patient Populations. 
  • Variation in interferon sensitivity and induction among strains of eastern equine encephalitis virus. 
  • Viral Replication Complexes Are Targeted by LC3-Guided Interferon-Inducible GTPases. 
  • [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis]. 
  • [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part II: radiobiological and immunologic strategies]. 
  • cGAS-STING pathway targeted therapies and their applications in the treatment of high-grade glioma. 
• 

  Keywords of People

  • Cianciolo, George James, Associate Professor Emeritus of Pathology, Pathology
  • Horner, Stacy M., Associate Professor in Integrative Immunobiology, Duke Science & Society
  • Taylor, Gregory Alan, Professor in Medicine, Integrative Immunobiology